

Survival patterns of COVID-19 pneumonia patients with false-negative PCR results transferred to the intensive care unit from the emergency department

Meltem Songur Kodik (✉ songurm@yahoo.com)

Ege University School of Medicine, Emergency Department <https://orcid.org/0000-0003-4565-3374>

Research Article

Keywords: COVID-19 Pandemic, COVID-19 RT-PCR Testing, Computed tomography, Intensive Care Units, Mortality

Posted Date: June 28th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-652047/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Objective

This study aimed to analyze factors associated with patient mortality in COVID-19 patients hospitalized in the intensive care unit (ICU) and provide data to help prioritize the most critical patients.

Design

Retrospective cohort study

Setting and participants

Data for 289 patients were analyzed by the XXX hospital's IT department.

Methods

A clinical retrospective cohort study was conducted in a tertiary hospital. Patients (n=289) with negative reverse transcription-polymerase chain reaction (RT-PCR) and positive chest computed tomography (CT) scan indicating COVID-19 were included in the research. Demographics, clinical characteristics, treatment modalities, and length of hospital stay were analyzed in relation to 30-day survival outcomes.

Results

The mean age of the patients was 69.04 ± 15.10 years (range 19-100), and 41.2% (n=119) were female. The mortality rate was 48.1% (n=139). There were statistically significant differences in laboratory findings, such as hemoglobin ($p=0.021$), lymphocyte counts ($p=0.046$), d-dimer ($p=0.009$), and lactate (<0.001) regarding one-month survival. Additionally, those hospitalized for more than 5 days had higher one-month survival rates (hazard ratio (HR)= 0.003, CI= 10.264-155.972). Moreover, intubated patients had a higher mortality risk during this period (HR=4.15, CI=1.53-11.20).

Conclusions and implications

The first five days of patients hospitalized in intensive care units due to COVID-19 pneumonia are critical. Besides, the need for intubation was another factor independently affecting survival. Clinicians should be alerted about the significance of these factors.

Introduction

The novel coronavirus disease 19 (COVID-19), which emerged in Wuhan in December 2019, has infected millions of people and evolved into a pandemic that has triggered a significant number of deaths and unprecedented global social and economic impact ¹. Although most of the patients were mild or asymptomatic, severe cases could challenge intensive care capacities in some periods due to the widespread prevalence of the COVID-19 infection ².

Some patients developed moderate to severe symptoms or had other underlying medical conditions, making them more vulnerable to the coronavirus. These patients were usually treated in intensive care units (ICUs)³. Identifying individuals at high risk and prioritizing their care will be of great advantage in order to use limited health resources efficiently and increase survival rates⁴.

Another clinical challenge is the accurate detection of COVID-19 patients. Based on a systemic review, studying negative real-time reverse transcription-polymerase chain reaction (RT-PCR) tests that were positive on a repeat test, the sensitivity of the RT-PCR tests vary between 71-98%⁵. The site and quality of sampling play a vital role in the accuracy of RT-PCR tests⁶. Also, the stage of disease and degree of viral multiplication or clearance is likely to affect the accuracy⁷.

In comparison, chest computed tomography (CT) has higher proven accuracy in diagnosing COVID-19, and it may be considered a primary detection method in epidemic areas⁸. Thus, when a patient is suspected of COVID-19 or showing typical symptoms but has a negative RT-PCR test, the chest CT scan is a powerful method to diagnose the disease⁹.

1.1 Objective

This study aimed to analyze factors associated with patient mortality in COVID-19 patients hospitalized in the intensive care unit (ICU) and provide data to help prioritize the most critical patients.

Methods

2.1 Study Design

This clinical retrospective cohort study was carried out by examining the files and records in the hospital automation system of patients who had a negative result on the RT-PCR test but diagnosed with COVID-19 pneumonia after observing typical positive CT findings and hospitalized in the anesthesiology and reanimation intensive care unit between March 11, 2020, and October 31, 2020. Ethical approval (Date: September 3, 2020, number: 20-9T/69) was received from the XXX Local Ethics Committee. Study reporting was done per the Strobe Guidelines¹⁰.

2.2 Setting

This study was done at the ... Hospital, emergency department. The research unit is a tertiary reference health center serving daily around 400 emergency admissions in ..., a city at the ... border with 4.1 million inhabitants.

In the hospital, RT-PCR-positive patients were admitted to the intensive care unit of the chest diseases department. In contrast, RT-PCR-negative patients requiring intensive care who had typical COVID-19 CT

findings were generally hospitalized to the anesthesiology and reanimation intensive care unit (A&R ICU). This is a special ICU assigned for COVID-19 patients in the study hospital. However, exceptionally, some RT-PCR-positive patients were admitted to the A&R ICU if they were transferred from another medical center or if the capacity of the other ICU was full.

2.3 Image Analysis

CT images were obtained using a 160-slice-CT scanner (Aquilion Prime, Toshiba Medical Systems Tokyo, Japan). The scanning parameters were; 120 kVp, 100-200 mA, automated dose reduction, 80x0.5 mm collimation, and reconstruction with a sharp algorithm at 0.5 mm slice thickness. CT images were reviewed with respect to COVID-19 by an experienced radiologist (author SB) blinded to RT-PCR results but aware of the epidemiologic history and clinical symptoms, such as fever and/or dry cough. After the examination, the radiologist decided whether the CT findings were positive or negative. Primary CT findings associated with COVID-19 were ground-glass opacity, consolidation, reticulation, and/or thickened interlobular septa, nodules, and lesion distribution in the left lung, right lung, or bilateral lungs.

2.4 Participants

An archive search was conducted by an experienced data analyst from the hospital's IT department using the International Statistical Classification of Diseases and Related Health Problems (ICD) code U07.3¹¹, the clinical code for COVID-19. Inclusion criteria were being above 18 years old, diagnosed by COVID-19 according to the case definition given by the Ministry of Health¹², and/or having COVID-19-compatible results in the chest CT scan. As shown in Figure 1, a total of 337 COVID-19 patients were detected, from which 48 RT-PCR positives were excluded. Finally, 289 patients were included in the study, of which 139 did not survive.

2.5 Variables

The dependent variable was 30-days survival. Patients were followed up until 30 days after admission to the emergency service (even if they were discharged earlier), and the outcome was reported as survived or died.

The independent numerical variables included age, results of the first clinical examination (temperature, respiratory rate, and peripheral oxygen saturation), duration of complaints (days), blood gas values, and blood test results. The categorical independent variables were sex, admission complaint, co-morbidity, symptom severity, treatments, co-infection, control PA chest radiography/CT scan, and hospital stay for more than 5 days. Evaluation of the symptom severity was performed as:

- Mild and moderate symptoms: Respiratory symptoms (cough, sputum, fever, chest pain) that do not reduce capillary oxygen saturation (SpO₂) to 90% or less.
- Severe symptoms: Dyspnea and low capillary oxygen saturation (SpO₂ ≤ 90%) ¹².

2.6 Statistical Analysis

Statistical analysis was performed with the Statistical Package for the Social Sciences program (SPSS for Windows, Version 25.0, Chicago, IL, USA). Results were presented as mean and standard deviations for numerical data and frequencies and percentages for categorical variables. The compatibility of variables to normal distribution was evaluated using the Kolmogorov-Smirnov test. Parametric variables were compared using the independent samples t-test. Additionally, Chi-square or Fisher's exact test was used to compare categorical variables. On the other hand, the Cox regression analysis was performed, and the effects of factors on survival were analyzed. For the statistical significance level, p<0.05 was considered sufficient.

Results

Data for 289 patients were analyzed. The mean age of the participants was 69.04±15.10 years (19-100), and 41.2% (n=119) were female. The mortality rate was 48.1% (n=139). There were statistically significant differences in some variables, such as lymphocyte numbers, d-dimer, and lactate related to one-month survival (Table 1).

The most often observed co-morbidities were cardiac failures, chronic obstructive pulmonary disease (COPD), malignancy, cardiovascular disease (CVD), and hypertension (Table 2). Other less frequently observed co-morbidities included diabetes mellitus (DM), dementia, coronary artery disease, or chronic kidney disease. Forty-seven (62.7%) patients diagnosed with malignancy died (Table 2).

There were three main complaints: respiratory symptoms (i.e., dyspnea and cough), fever, and delirium. Less frequently observed complaints, such as nausea, diarrhea, or disordered general health, were included in the 'other symptoms' group. Eighteen patients had mild symptoms, and only 2 (11.1%) of those died, whereas in patients with moderate and severe symptoms, this ratio was much higher (52.7% and 50%, respectively). Intubation and inotropic treatment caused a significant difference in the one-month survival. Co-infection was present in 77 (26.6%) of the patients, and the focuses of infection were the urinary tract, sepsis, lung, or tissues (Table 2).

Those hospitalized for more than 5 days were less likely to die within one month. Additionally, intubated patients had a higher mortality risk (Table 3).

In the survival analysis, patients with a hospital stay of more than five days had significantly higher survival rates than those who were hospitalized five days or less (Figure 1). Also, a statistically significant

difference was found between survival times in patients with and without intubation in the survival analysis (Figure 2).

Key Results

There were statistically significant differences in laboratory findings, such as hemoglobin, lymphocyte counts, lactate dehydrogenase (LDH), d-dimer, and lactate related to one-month survival. Additionally, hospitalization for more than 5 days and intubation were factors that independently affected one-month survival. A hospital stays of more than five days had a positive effect on survival, while the need for intubation had a negative impact.

Discussion

The outbreak of novel coronavirus pneumonia is an unprecedented public health issue due to being large-scale spread that overloaded medical services and resulted in excessive usage of medical resources¹. A widely used method to diagnose COVID-19 is the PCR tests. However, these tests can sometimes give false-negative results. Some reasons for these misdiagnoses are sampling or transport errors and mutations in probe-target regions in the SARS-CoV-2 genome¹³. If a patient is suspected of having COVID-19, but RT-PCR is negative, a chest CT scan can effectively support diagnosis⁹. In a study with 1014 patients in Wuhan that references positive RT-PCR cases, the sensitivity of chest CT for COVID-19 was estimated as 97% (580 of 601 patients).

Moreover, in a comprehensive evaluation among 308 patients with negative RT-PCR results and positive chest CT findings, 147 (48%) of these were revised as highly possible cases and 103 (33%) as probable cases⁸. This study can contribute to the literature by analyzing patients with negative PCR results and positive chest CT findings and revealing the factors affecting mortality. Thus, these findings may allow clinicians to prioritize the care for individuals, assist resource allocations, and reduce fatality rates.

Mortality rates due to COVID-19 are very high in hospitalized elderly patients¹⁴⁻¹⁶. Besides, pre-existing co-morbidity and disease severity are associated with poor prognosis in these patients¹⁷. Moreover, in elderly patients hospitalized for COVID-19, male sex, crackles, high respiratory oxygen requirement, and bilateral and peripheral infiltrates on chest radiographs are independent risk factors for mortality¹⁵. In line with previous studies in this research, symptom severity, co-morbidity, having respiratory symptoms, and positive findings on chest X-ray were associated with poor prognosis. However, we found no relationship between sex and mortality.

In addition to symptoms such as dyspnea, increased LDH, D-dimer, PCT, ferritin, and leukocyte counts, and decreased lymphocyte counts have been specified as laboratory parameters that can be used to predict mortality in COVID-19 patients¹⁸⁻²⁰. Moreover, hemoglobin (HGB) and hematocrit (HCT) values are also critical for these patients. In a study of COVID-19 cases hospitalized in an intensive care unit in Ankara, mean values of HGB and HCT were below the normal range²¹. Reportedly, the anomalies of HGB

and HCT were associated with co-morbidity, and the reasons can be bone marrow being unable to produce enough red blood cells to carry oxygen or the lung damages caused by COVID-19, making gaseous exchange difficult ²². Likewise, in our study, similar results were obtained with previous publications, and also hemoglobin and hematocrit were lower, especially in patients who did not survive for a month. Furthermore, lactate levels of the non-survivors were significantly higher than the survivors, which is reportedly a predictor of severe pneumonia ²⁰.

In a multicenter cohort study that included only elderly emergency patients (>65, mean age 77.7) with COVID-19, 28% of the subjects had delirium at admission ²³. In our study, this rate was lower (8.7%). The main reason for this difference could be the difference in the study populations. Indeed, our study included patients older than 18 years of age, with a mean age of 69 years.

The most common co-morbidity in our study was hypertension, similar to a study in 5700 patients hospitalized with COVID-19 in New York City Area ²⁴. Malignancy increases the risk of death due to COVID-19 infection ^{25,26}. Likewise, in our study, malignancy increased mortality, but our rate was higher than in previous studies. This difference may be due to the diversity of the departments where the studies were conducted. It is not surprising that mortality rates were high in the research performed in the ICU.

Consistent with a retrospective study in which the mortality rate was estimated as 57%, another factor that increased fatality in intensive care COVID-19 patients was the presence of co-infection ²⁷. Therefore, antibiotic therapy should be optimized in critically ill patients with COVID-19 in the ICU.

Furthermore, this study reinforced that the need for intubation should alert clinicians to the high mortality rate. In a single-center pilot study with critically ill patients, 76% of intubated patients died [28]. In another study, this rate was 81.1% ²⁹.

Inotropic agents are frequently used in patients with concerns about severely reduced cardiac output, indicating a poor prognosis ³⁰. Indeed, patients requiring inotropic therapy had a lower one-month survival rate in this study.

The length of stay for critically ill patients is lower for the non-survivors than for survivors ³¹. The median length of ICU stay was reported between 4 and 11 days for patients who died in the ICU ^{4,31}. Our findings were consistent with previous studies. Additionally, in the regression model, intubation and hospital stay were factors independently affecting survival. The higher mortality rates in those who stayed in the hospital for less than 5 days may be related to the poor condition of the patients admitted to the intensive care unit. In other words, patients may respond better to treatment after the initial critical situation has passed, and therefore mortality rates may have decreased.

This study should be interpreted in light of some limitations. Firstly, it is a retrospective investigation conducted in a single emergency service and intensive care unit. Secondly, no long-term outcomes or quality of life were tracked in the survivors. Finally, at the beginning of the coronavirus outbreak,

treatments were difficult due to the facilities. Specifically, most of the frequently used COVID-19 medicines today were absent or low in supply, and plasma treatment was not possible in the first weeks or months of the pandemic.

Conclusions And Implications

Some of the patients hospitalized in the intensive care unit are false negative for COVID-19. The ability of clinicians to predict patients with poor prognoses can help to optimize ICU use. This study showed that the first five days of patients hospitalized in intensive care units due to COVID-19 pneumonia are critical. Additionally, the need for intubation was another factor that clinicians should be alerted about, as it is a factor independently affecting survival. Furthermore, some laboratory parameters such as high D-dimer and lactate levels, as well as clinical conditions, such as malignancy, co-infection, and co-morbidity, are factors associated with mortality. So, these should also be carefully investigated in intensive care patients with COVID-19 pneumonia. These findings can also be beneficial in providing the optimum delivery to the most in need by carefully allocating the medical resources.

Declarations

Competing interests: The author declares no competing interests.

References

- [1] R. B. Serafim, P. Póvoa, V. Souza-Dantas, A. C. Kalil, and J. I. F. Salluh, "Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review," *Clin. Microbiol. Infect.*, no. xxxx, pp. 1–8, 2020, doi: 10.1016/j.cmi.2020.10.017.
- [2] A. Remuzzi and G. Remuzzi, "COVID-19 and Italy: what next?," *Lancet (London, England)*, vol. 395, no. 10231, pp. 1225–1228, Apr. 2020, doi: 10.1016/S0140-6736(20)30627-9.
- [3] C. Wu, X. Chen, and Y. Cai, "Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China," vol. 180, no. 7, pp. 934–943, 2020, doi: 10.1001/jamainternmed.2020.0994.
- [4] S. A. Namendys-Silva *et al.*, "Outcomes of patients with COVID-19 in the intensive care unit in Mexico: A multicenter observational study," *Hear. Lung*, vol. 000, pp. 1–5, 2020, doi: 10.1016/j.hrtlng.2020.10.013.
- [5] J. W. Gp and F. Penny, "Interpreting a covid-19 test result," vol. 1808, no. May, pp. 1–7, 2020, doi: 10.1136/bmj.m1808.
- [6] H. Province, "Detection of SARS-CoV-2 in Different Types of Clinical Specimens," vol. 323, no. 18, pp. 1843–1844, 2020, doi: 10.1001/jama.2020.1585.

- [7] N. Sethuraman, S. Stanleyraj, Y. City, A. Ryo, and Y. City, "Interpreting Diagnostic Tests for SARS-CoV-2," vol. 2019, pp. 2019–2021, 2020.
- [8] L. X. Tao Ai, Zhenlu Yang, Hongyan Hou, Chenao Zhan, Chong Chen, Wenzhi Lv, Qian Tao, Ziyong Sun, "Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases," *Radiology*, vol. 296, no. 2, pp. E32–E40, 2020, doi: 10.1148/radiol.2020200642.
- [9] B. Brogna *et al.*, "Typical CT findings of COVID-19 pneumonia in patients presenting with repetitive negative RT-PCR," *Radiography*, no. xxxx, 2020, doi: 10.1016/j.radi.2020.09.012.
- [10] E. Von Elm *et al.*, "The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies," *Int. J. Surg.*, vol. 12, pp. 1495–1499, 2014, doi: 10.1016/j.ijsu.2014.07.013.
- [11] "ICD-10-CM coma, stroke codes require more specific documentation," *JustCoding News: Inpatient*, 2012. .
- [12] Republic of Turkey Ministry of Health, "COVID-19 (SARS-CoV-2 INFECTION) GUIDE: Study of Scientific Board," vol. 19, 2020.
- [13] I. Trisnawati, R. El Khair, D. A. Puspitarani, A. R. Fauzi, and Gunadi, "Prolonged nucleic acid conversion and false-negative RT-PCR results in patients with COVID-19: A case series," *Ann. Med. Surg.*, vol. 59, no. 1, pp. 224–228, 2020, doi: 10.1016/j.amsu.2020.09.040.
- [14] L. C. Blomaard *et al.*, "Frailty is associated with in-hospital mortality in older hospitalised COVID-19 patients in the Netherlands: the COVID-OLD study," *Age Ageing*, vol. 50, no. 3, pp. 631–640, May 2021, doi: 10.1093/ageing/afab018.
- [15] A. Mendes *et al.*, "Predictors of In-Hospital Mortality in Older Patients With COVID-19: The COVIDAge Study," *J. Am. Med. Dir. Assoc.*, vol. 21, no. 11, pp. 1546-1554.e3, 2020, doi: 10.1016/j.jamda.2020.09.014.
- [16] R. K. Owen *et al.*, "Comparing associations between frailty and mortality in hospitalised older adults with or without COVID-19 infection: a retrospective observational study using electronic health records," *Age Ageing*, vol. 50, no. 2, pp. 307–316, Feb. 2021, doi: 10.1093/ageing/afaa167.
- [17] T. Chen *et al.*, "Clinical Characteristics and Outcomes of Older Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Single-Centered, Retrospective Study," *J. Gerontol. A. Biol. Sci. Med. Sci.*, vol. 75, no. 9, pp. 1788–1795, Sep. 2020, doi: 10.1093/gerona/glaa089.
- [18] H. Sun, R. Ning, Y. Tao, C. Yu, and X. Deng, "Risk Factors for Mortality in 244 Older Adults With COVID-19," pp. 19–23, 2020, doi: 10.1111/jgs.16533.

- [19] M. P. Toutkaboni *et al.*, “Demographics , laboratory parameters and outcomes of 1061 patients with coronavirus disease 2019: a report from Tehran , Iran,” *New Microbes New Infect.*, vol. 38, p. 100777, 2020, doi: 10.1016/j.nmni.2020.100777.
- [20] D. Ose, A. Berzins, K. Grigorovica, A. Klucniks, and O. Sabelnikovs, “Lactate as a Predictor in Severe Pneumonia,” *Acta Chir. Latv.*, vol. 15, no. 1, pp. 29–34, 2016, doi: 10.1515/chilat-2016-0006.
- [21] H. Bodur *et al.*, “International Immunopharmacology Clinical and laboratory features of COVID-19: Predictors of severe prognosis,” *Int. Immunopharmacol.*, vol. 88, no. September, p. 106950, 2020, doi: 10.1016/j.intimp.2020.106950.
- [22] D. K. Djakpo *et al.*, “Blood routine test in mild and common 2019 coronavirus (COVID-19) patients,” vol. 0, no. March, pp. 1–5, 2020.
- [23] M. Kennedy *et al.*, “Delirium in Older Patients With COVID-19 Presenting to the Emergency Department,” vol. 3, no. 11, pp. 1–12, 2020, doi: 10.1001/jamanetworkopen.2020.29540.
- [24] S. Richardson *et al.*, “Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area,” *JAMA*, vol. 323, no. 20, p. 2052, May 2020, doi: 10.1001/jama.2020.6775.
- [25] V. Mehta *et al.*, “Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System,” no. july, pp. 19–26, 2020, doi: 10.1158/2159-8290.CD-20-0516.
- [26] R. Narozniak, “No Title,” *Oncology Nursing News*, 2020. .
- [27] M. C. Soriano, C. Vaquero, A. Ortiz-Fernández, A. Caballero, A. Blandino-Ortiz, and R. de Pablo, “Low incidence of co-infection, but high incidence of ICU-acquired infections in critically ill patients with COVID-19,” *J. Infect.*, Sep. 2020, doi: 10.1016/j.jinf.2020.09.010.
- [28] M. Luo *et al.*, “Intubation, mortality, and risk factors in critically ill Covid-19 patients: A pilot study,” *J. Clin. Anesth.*, vol. 67, p. 110039, Dec. 2020, doi: 10.1016/j.jclinane.2020.110039.
- [29] Y. Tu *et al.*, “Risk factors for mortality of critically ill patients with COVID-19 receiving invasive ventilation.,” *Int. J. Med. Sci.*, vol. 18, no. 5, pp. 1198–1206, 2021, doi: 10.7150/ijms.50039.
- [30] S. Fox, R. Vashisht, M. Siuba, and S. Dugar, “Evaluation and management of shock in patients with COVID-19,” *Cleve. Clin. J. Med.*, Jul. 2020, doi: 10.3949/ccjm.87a.ccc052.
- [31] E. M. Rees *et al.*, “COVID-19 length of hospital stay: A systematic review and data synthesis,” *BMC Med.*, vol. 18, no. 1, 2020, doi: 10.1186/s12916-020-01726-3.

Tables

Table 1: Comparison of numerical variables concerning one-month survival

	Survival	n	Mean	SD	t	p
Age (year)	Died	139	70.64	13.88	1.735	0.084
	Survived	150	67.57	16.07		
Respiratory rate (/min)	Died	81	20.81	4.66	1.747	0.082
	Survived	86	22.00	4.10		
Pulse (/min)	Died	95	105.64	25.49	2.812	0.005
	Survived	111	96.42	21.57		
Temperature (°C)	Died	62	36.42	0.90	0.355	0.723
	Survived	57	36.36	0.77		
Capillary saturation (%)	Died	106	91.86	8.09	0.230	0.818
	Survived	125	91.62	7.90		
Duration of complaint (days)	Died	130	4.53	8.96	1.669	0.097
	Survived	130	3.14	3.19		
Leukocyte counts (/mm ³)	Died	139	16658	24669	0.417	0.677
	Survived	150	15513	21970		
Lymphocyte counts (μL)	Died	139	2137.48	4644.58	2.003	0.046
	Survived	150	3913.07	9723.11		
Hemoglobin (g/dl)	Died	139	11.06	2.74	2.325	0.021
	Survived	150	11.78	2.51		
Hematocrit (%)	Died	139	34.78	8.22	2.702	0.007
	Survived	150	37.29	7.62		
Troponin (ug/L)	Died	129	125.82	363.73	1.137	0.257
	Survived	137	84.56	213.05		
LDH (U/L)	Died	78	579.45	902.45	2.721	0.008
	Survived	74	297.88	140.40		
D-dimer (mg/dl)	Died	117	3051.54	1549.44	2.620	0.009
	Survived	123	2535.23	1503.42		
Ferritin (ng/mL)	Died	7	445.76	457.13	1.085	0.306
	Survived	4	187.60	118.90		

Lactate (mmol/L)	Died	138	4.23	4.12	3.668	<0.001
	Survived	147	2.79	2.11		
Hospitalization (hours)	Died	139	265.07	287.79	1.219	0.224
	Survived	150	304.15	257.00		

SD: standard deviation, t: Independent samples t-test value, LDH: Lactate dehydrogenase

Table 2: Comparison of categorical variables regarding one-month survival

		One-month survival				χ^2	p
		Died		Survived			
		n	%	n	%		
Sex	Female	53	44.5	66	55.5	1.026	0.311
	Male	86	50.6	84	49.4		
Admission Complaints							
Respiratory symptoms	No	54	56.8	41	43.2	4.336	0.037
	Yes	85	43.8	109	56.2		
Fever	No	116	48.7	122	51.3	0.223	0.637
	Yes	23	45.1	28	54.9		
Delirium	No	123	46.6	141	53.4	2.773	0.096
	Yes	16	64.0	9	36.0		
Other symptoms	No	86	44.3	108	55.7	3.355	0.067
	Yes	53	55.8	42	44.2		
Co-morbidity							
Cardiac failure	No	11	39.3	17	60.7	0.964	0.326
	Yes	128	49.0	133	51.0		
COPD	No	109	47.4	121	52.6	0.225	0.635
	Yes	30	50.8	29	49.2		
Malignancy	No	125	48.4	133	51.6	0.120	0.729
	Yes	14	45.2	17	54.8		
CVD	No	92	43.0	122	57.0	8.613	0.003
	Yes	47	62.7	28	37.3		
Hypertension	No	130	48.5	138	51.5	0.249	0.618
	Yes	9	42.9	12	57.1		
Other co-morbidities	No	69	50.7	67	49.3	0.716	0.397
	Yes	70	45.8	83	54.2		
Symptom severity	Mild	52	48.1	56	51.9	0.000	0.989
		87	48.1	94	51.9		

	Moderate	49	52.7	44	47.3		
	Severe	86	50.0	86	50.0		
Second PCR result	Negative	120	45.6	143	54.4	0.060	1.000
	Positive	4	50.0	4	50.0		
Inotrope treatment	No	44	25.7	127	74.3	85.590	<0.001
	Yes	95	81.2	22	18.8		
Intubation	No	37	23.3	122	76.7	88.805	<0.001
	Yes	102	79.1	27	20.9		
Co-infection**	No	91	42.9	121	57.1	8.527	0.003
	Yes	48	62.3	29	37.7		
Urinary track	No	115	45.8	136	54.2	3.976	0.046
	Yes	24	63.2	14	36.8		
Lung	No	121	46.2	141	53.8	4.114	0.043
	Yes	18	66.7	9	33.3		
Sepsis	No	120	45.3	145	54.7	10.121	0.001
	Yes	19	79.2	5	20.8		
Tissue	No	136	47.9	148	52.1	0.289	0.674*
	Yes	3	60.0	2	40.0		
Culture positivity	Absent	92	42.8	123	57.2	12.792	0.002
	Present	47	65.3	25	34.7		
Control PA chest radiography	Regression	17	24.6	52	75.4	24.315	<0.001
	Stable	33	40.7	48	59.3		
	Progression	28	73.7	10	26.3		
Hospital stay for more than 5 days	No	44	68.8	20	31.3	14.046	<0.001
	Yes	95	42.2	130	57.8		

χ^2 : Chi-Square test value, *:Fisher's Exact test, **: In some patients, multiple co-infections were observed

Table 3: Cox-regression analysis computer output showing factors independently affecting one-month survival

	B	SE	Wald	p	Exp(B)	95.0% CI for Exp(B)	
						Lower	Upper
Pulse /min	0.006	0.011	0.36	0.548	1.01	0.99	1.03
Hemoglobin (g/dl)	0.013	0.103	0.017	0.896	1.01	0.83	1.24
Blood urea nitrogen (mg/dl)	0.001	0.003	0.073	0.788	1.00	1.00	1.01
LDH (U/L)	0	0.001	0.33	0.565	1.00	1.00	1.00
D-dimer (mg/dl)	0	0	0.019	0.891	1.00	1.00	1.00
Lactate (mmol/L)	0.092	0.063	2.131	0.144	1.10	0.97	1.24
Inotrope treatment (Yes vs. No)	0.732	0.584	1.571	0.210	2.08	0.66	6.53
Intubation (Yes vs. No)	1.422	0.507	7.864	0.005	4.15	1.53	11.20
Co-infection (Yes vs. No)	0.058	0.474	0.015	0.902	1.06	0.42	2.68
Fever at admission			3.875	0.144			
Fever at admission (Yes vs. No)	1.347	0.694	3.769	0.052	3.85	0.99	14.98
Fever at admission (No fever vs. No)	0.765	0.678	1.274	0.259	2.15	0.57	8.12
Hospital stay for more than 5 days (Yes vs. No)	-3.689	0.694	28.245	<0.001	0.03	0.01	0.10
Symptom severity			0.337	0.845			
Symptom severity (Moderate vs. mild)	1.52	3.851	0.156	0.693	4.57	0.00	8660.53
Symptom severity (Severe vs. mild)	1.306	3.846	0.115	0.734	3.69	0.00	6927.60
Malignancy (Present vs. Absent)	0.236	0.443	0.283	0.595	1.27	0.53	3.02

LDH: Lactate dehydrogenase

Figures




Figure 1

Figure 1: Survival chart based on hospitalization time




Figure 2

Figure 2: Survival chart according to intubation